[In vitro and in vivo studies with interleukin 2 (IL-2) and various immunostimulants in a patient with AIDS].
We report on a lethal course of an acquired immunodeficiency syndrome (AIDS) in a young female patient. She had spent her vacancies six years before diagnosis in Haiti, where a sexual intercourse with a Haitian man had occurred. Leading clinical symptoms consisted of recurrent Herpes simplex infections of the genital and perianal region as well as unexplained high temperatures. There were some typical laboratory and immunologic features of this disease with leukopenia, hypergammaglobulinemia, cutaneous anergy, a reduction of peripheral T-lymphocytes (OKT 3) and an almost complete loss of OKT 4 (helper cells) positive lymphocytes. The mitogenic response upon stimulation with allogeneic cells (MLC) or with the mitogens PHA, Con A and PWM was significantly reduced. There was no measurable interleukin-2 (IL-2) secretion of peripheral blood lymphocytes. Several immunostimulators (thymopentin, inosiplex, bestatin) were tested in lymphocyte proliferation assays in vitro. The mitogenic response could not be enhanced by neither of these substances. A clinical trial with Delimmun (inosiplex) for 14 days did not show any clinical or immunologic improvement in this patient. The intravenous application of high dose immunoglobulin G was without any observable effect. The proliferation inducing capacity of a highly purified IL-2 preparation on the AIDS cells in vitro led us to a clinical trial with this substance. We applied 100 Bödeker units of IL-2 per kg body weight and day subcutaneously for 16 days. A therapeutical effect, however, could not be observed. Cell marker analyses did not show significant changes in lymphocyte subpopulation composition under IL-2 therapy. There was an increase in the spontaneous cell proliferation 14 days after start of IL-2 therapy. The PHA- and IL-2 response of the AIDS cells, however, was unchanged. It cannot be excluded that an administration of IL-2 in earlier stages of AIDS may have beneficial effects.
Vaith
P
P
Maas
D
D
Feigl
D
D
Hauke
G
G
Lang
B
B
Oepke
G
G
Stierle
H E
HE
Bross
K J
KJ
Andreesen
R
R
Gross
G
G
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000917:Antibody Formation / Q000187:drug effects; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007542:Inosine Pranobex / Q000627:therapeutic use; D007376:Interleukin-2 / Q000008:administration & dosage*; D007930:Leucine / Q000031:analogs & derivatives / Q000627:therapeutic use; D007958:Leukocyte Count; D008213:Lymphocyte Activation / Q000187:drug effects; D007959:Lymphocyte Culture Test, Mixed; D008214:Lymphocytes / Q000276:immunology; D010446:Peptide Fragments / Q000627:therapeutic use; D016305:Thymopentin; D013946:Thymopoietins / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D007376:Interleukin-2; D010446:Peptide Fragments; D013946:Thymopoietins; D007930:Leucine; C012211:ubenimex; D016305:Thymopentin; D007542:Inosine Pranobex
In-vitro- und In-vivo-Studien mit Interleukin-2 (IL-2) und verschiedenen Immunstimulanzien bei einer Patientin mit AIDS.